Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2

Authors: Shujun Feng, Wenjing Pan, Ye Jin, Jianhua Zheng

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

Ovarian cancer (OC) is a major cancer-related mortality among women. Recent studies suggest that many microRNAs (miRNAs) were dysregulated and involved in tumorigenesis of OC. The present study investigated the role of miR-25 in the development and progression of OC. The expression of miR-25 was increased in OC tissues and cell lines. Inhibition of miR-25 remarkably suppressed proliferation, migration, and invasion of OC cells. Large tumor suppressor 2 (LATS2), a tumor suppressor, was confirmed to be a direct target of miR-25 in OC cells. Moreover, restoration of LATS2 significantly attenuated the oncogenic effects of miR-25. Together, our data suggest an oncogenic role of miR-25 in OC and a potentially novel diagnostic and therapeutic target for OC treatment.
Literature
1.
Kim K, Zang R, Choi SC, Ryu SY, Kim JW. Current status of gynecological cancer in China. J Gynecol Oncol. 2009;20:72–6.CrossRef
2.
Suh DH, Kim JW, Kim K, Kim HJ, Lee KH. Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol. 2013;24:66–82.CrossRef
3.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.CrossRef
4.
Parikh A, Lee C, Peronne J, Marchini S, Baccarini A, Kolev V, et al. MicroRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 2014;5:2977.CrossRef
5.
Kentwell J, Gundara JS, Sidhu SB: Noncoding RNAs in endocrine malignancy. The oncologist 2014
6.
Alsaleh G, Gottenberg JE. Characterization of microRNAs and their targets. Methods Mol Biol. 2014;1142:55–63.CrossRef
7.
Li W, Liu Z, Chen L, Zhou L, Yao Y: MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2. FEBS letters. 2014;588(9):1608–15.
8.
Xia J, Guo X, Yan J, Deng K: The role of mir-148a in gastric cancer. Journal of cancer research and clinical oncology. J Cancer Res Clin Oncol. 2014;140(9):1451–56.
9.
Li S, Li Y, Wen Z, Kong F, Guan X, Liu W. microRNA-206 overexpression inhibits cellular proliferation and invasion of estrogen receptor alphapositive ovarian cancer cells. Mol Med Rep. 2014;9:1703–8.CrossRef
10.
Shen W, Song M, Liu J, Qiu G, Li T, Hu Y, et al. Mir-26a promotes ovarian cancer proliferation and tumorigenesis. PLoS One. 2014;9:e86871.CrossRef
11.
Wang X, Meng X, Li H, Liu W, Shen S, Gao Z: MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer. Clin Translational Oncol: Off Publ Federat Spanish Oncol Soc Natl Cancer Institute Mexico. Biochem Biophys Res Commun. doi:10.​1007/​s12094-014-1178-6.
12.
Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, et al. Tumour angiogenesis regulation by the mir-200 family. Nat Commun. 2013;4:2427.CrossRef
13.
Wang S, Zhao X, Wang J, Wen Y, Zhang L, Wang D, et al. Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. Med Oncol. 2013;30:681.CrossRef
14.
Xu FX, Su YL, Zhang H, Kong JY, Yu H, Qian BY. Prognostic implications for high expression of mir-25 in lung adenocarcinomas of female non-smokers. Asian Pacific J Cancer Prev: APJCP. 2014;15:1197–203.CrossRef
15.
Zhao H, Wang Y, Yang L, Jiang R, Li W. Mir-25 promotes gastric cancer cells growth and motility by targeting RECK. Mol Cell Biochem. 2014;385:207–13.CrossRef
16.
Xu X, Chen Z, Zhao X, Wang J, Ding D, Wang Z, et al. MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2012;421:640–5.CrossRef
17.
Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z. Mir-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2012;27:594–8.PubMed
18.
Yabuta N, Fujii T, Copeland NG, Gilbert DJ, Jenkins NA, Nishiguchi H, et al. Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the drosophila tumor suppressor gene lats/warts. Genomics. 2000;63:263–70.CrossRef
19.
Yu T, Bachman J, Lai ZC. Evidence for a tumor suppressor role for the large tumor suppressor genes LATS1 and LATS2 in human cancer. Genetics. 2013;195:1193–6.CrossRef
20.
Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of angiomotin by the LATS1/2 protein kinases. Proc Natl Acad Sci U S A. 2013;110:17368–73.CrossRef
21.
Dai X, She P, Chi F, Feng Y, Liu H, Jin D, et al. Phosphorylation of angiomotin by LATS1/2 kinases inhibits f-actin binding, cell migration, and angiogenesis. J Biol Chem. 2013;288:34041–51.CrossRef
22.
Visser S, Yang X. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle. 2010;9:3892–903.CrossRef
23.
Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11:1380–5.CrossRef
24.
Fang L, Du WW, Yang W, Rutnam ZJ, Peng C, Li H, et al. Mir-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle. 2012;11:4352–65.CrossRef
25.
Yang X, Yu J, Yin J, Xiang Q, Tang H, Lei X. Mir-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. Die Pharmazie. 2012;67:645–51.PubMed
26.
Xia Y, Gao Y: MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2. Biochem Biophys Res Commun. 2014;447(3):446--51.
Metadata
Title
MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2
Authors
Shujun Feng
Wenjing Pan
Ye Jin
Jianhua Zheng
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2546-0

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue

Research Article

Upregulation of mediator MED23 in non-small-cell lung cancer promotes the growth, migration, and metastasis of cancer cells

Research Article

Somatic mutations of the HER2 in metastatic breast cancer

Research Article

Nucleotidyl transferase TUT1 inhibits lipogenesis in osteosarcoma cells through regulation of microRNA-24 and microRNA-29a

Research Article

Genetic association between cyclin D1 polymorphism and breast cancer susceptibility

Research Article

Elevated microRNA-185 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in clear cell renal cell carcinoma

Research Article

Overexpression of GOLPH3 protein is associated with worse prognosis in patients with epithelial ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits